Abstract: Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.

Abstract: Polypeptides useful in the preparation of vaccine compositions against RSV are provided. Also disclosed are methods of enhancing subdominant antibody responses in a subject.

Abstract: Materials and methods for the prevention of Ebola virus are provided. This disclosure is related to vaccine compositions comprising one or more Ebola vims (EBOV) glycoproteins as well as methods of preventing an EBOV infection comprising administering such compositions. In particular, modified EBOV glycoproteins are provided that form trimers and induce an immune response.

Abstract: The invention relates to heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment.

Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

Abstract: Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.

Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

Abstract: A method for training flight crew in a flight simulator that comprises opening a database of flight events, wherein each flight event has desired flight crew performance (DFCP) data that comprise user data associated with expected user actions; generating a training session by selecting at least one flight event from the database of flight events; running the training session in the flight simulator with at least one student; gathering student data based on student actions during the training session; and comparing the gathered student data to the DFCP data corresponding to the same at least one flight event to produce a comparison result. The obtained comparison result allows establishing whether required flight competencies associated with the generated training session have been reached by the student.

Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

Abstract: The present invention provides immunogens that protect against RSV infection. The present invention also provides antibody proteins that protect against RSV infection. Such immunogens and antibody proteins are produced based on three-dimensional models also included in the invention. One model is of a complex between motavizumab and its antibody-binding domain on RSV fusion (F) protein. A second model is of a complex between 10 IF antibody and its antibody-binding domain on RSV F protein. The immunogens disclosed herein have been modified to elicit a humoral response against RSV F protein without eliciting a significant cell-mediated response against RSV. Such immunogens can comprise a scaffold into which RSV contact residues are embedded. The present invention also includes methods that utilize the disclosed three-dimensional models to produce immunogens and antibody proteins of the present invention.